Related Experiment Videos
Screening for heparin binding variants of antithrombin
1University of Cambridge, Department of Haematology, Addenbrooke's Hospital.
Journal of Clinical Pathology
|June 1, 1991
Summary
A new chromogenic assay can identify antithrombin deficiency, including heparin binding defects. Optimized incubation times are crucial for accurate screening of antithrombin (AT) variants.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Hematology
Background:
- Antithrombin deficiency is a risk factor for thrombosis.
- Existing assays may fail to detect heparin binding variants of antithrombin.
- Accurate identification of antithrombin variants is essential for patient management.
Purpose of the Study:
- To describe a novel chromogenic assay for identifying antithrombin deficiency.
- To optimize assay conditions for detecting heparin binding defects.
- To differentiate heparin binding variants from other antithrombin deficiencies.
Main Methods:
- Development of a chromogenic assay.
- Optimization of heparin concentration and incubation time.
- Evaluation of assay sensitivity for antithrombin variants.
Main Results:
- Assay sensitivity for heparin binding variants was impaired with incubation times >30 seconds.
- Commercial assays with longer incubation times may miss these variants.
- The described assay successfully identifies heparin binding antithrombin defects.
Conclusions:
- A simple, two-stage chromogenic assay can identify heparin binding antithrombin variants.
- Assay optimization, particularly incubation time, is critical for detecting specific antithrombin defects.
- This assay improves the screening for antithrombin deficiency, aiding in diagnosis and treatment.